Increasing evidence suggests a relationship between oxidative stress and a-synuclein aggregation, the primary pathological hallmark of Parkinson disease (PD). However, a direct causal relationship has not yet been established in vivo in mouse models of PD. Superoxide dismutase 2 (SOD2) is rate limiting in the antioxidant machinery of the mitochondria and even its partial deficiency elevates oxidative stress in mice. Therefore, in order to investigate a possible interaction between oxidative stress and a-synuclein aggregation in vivo, a transgenic model of PD with haplodeficiency for SOD2 was generated on the basis of the well-characterized murine (Thy-1)-h[A30P]-a-synuclein transgenic line. In comparison with littermate controls with full SOD2 capacity, a-synuclein transgenic mice with partial SOD2 deficiency exhibited a significantly more advanced stage of synucleinopathy at 16 months, as demonstrated by higher median PK-PET blot scores (p < 0.01) and a greater amount of truncated a-synuclein in the insoluble fraction of homogenized brains (p < 0.05). These results show that compromising the capacity to scavenge free radicals can exacerbate a-synuclein aggregation, indicating that elevated levels of oxidative stress could modulate the progression of PD.
INTRODUCTION
a-Synuclein aggregation and mitochondrial dysfunction are 2 processes heavily implicated in the pathogenesis of Parkinson disease (PD). Missense mutations (e.g. A53T [1] , A30P [2] , E46K [3] ), duplications (4) (5) (6) (7) , and triplications (7) (8) (9) of the a-synuclein gene underlie rare inherited forms of the disease with early onset, while genes linked to mitochondria and oxidative stress (e.g. parkin [10] , PINK-1 [11] , DJ-1 [12] ) have also demonstrated causal roles. Increasing evidence supports an interaction between a-synuclein and mitochondrial dysfunction, suggesting that these 2 disease mechanisms are not necessarily mutually exclusive and could converge on the same pathological pathway. Indeed, transgenic mice expressing mutant human a-synuclein exhibit inclusion formation and mitochondrial degeneration associated with significantly diminished complex IV activity in brainstem and spinal-cord neurons (13) . Similarly, reduced complex I capacity has been detected in the substantia nigra following expression of double-mutant human a-synuclein (14) . Furthermore, the sensitivity of transgenic mice to the neurotoxicity of mitochondrial complex I inhibitors is exacerbated by the overexpression of wild type or mutant human a-synuclein (15, 16) , whereas a-synuclein-null mice instead demonstrate increased resistance to this neurotoxicity (17, 18) . Moreover, asynuclein aggregation can be induced in rodents by the pharmacological inhibition of mitochondrial complex I (19, 20) , and oxidative stress induces a-synuclein aggregation in vitro (21, 22) . The relationship between a-synuclein aggregation and mitochondrial dysfunction could represent a positive feedback loop, in which either stimulus could trigger a selfperpetuating process resulting in an analogous outcome. Crosstalk with other cellular machinery could even recruit separate disease mechanisms, thus intensifying the pathological effect. Indeed, since the primary source of chemical energy for the cell is provided by a combination of the mitochondrial electron transport chain and the mitochondrial oxidative phosphorylation machinery, impairment of the respiratory chain would reduce the capacity of mitochondria to supply energy to the cell, thus affecting energy-dependent processes like cellular protein homeostasis. The ubiquitinproteasome system is heavily reliant on ATP, and so clearance of damaged proteins would become hindered, which could lead to the build-up of more a-synuclein aggregates, thus aggravating the pathogenic situation further (23, 24) .
The consequence of dysfunctional metabolism in mitochondria is not only an energy crisis, but also enhanced reactive oxygen species (ROS) formation (25, 26) . Even under normal conditions, mitochondrial complexes I and III provide a continuous supply of prematurely leaked electrons that can reduce molecular oxygen to produce superoxide radicals (27) (28) (29) . This process is drastically amplified if mitochondrial respiration is impaired. Inhibition of complex I activity in dopaminergic neurons results in increased production of ROS and subsequent oxidative damage of proteins, lipids, and DNA (30) . Because of the inherent threat posed by oxidative stress, it is imperative that mitochondria be associated with antioxidant defense mechanisms to protect their redox environment. One of the primary enzymatic systems charged with carrying out this duty is superoxide dismutase (SOD), which is specifically responsible for the detoxification of superoxide radicals (31) . There are multiple isoforms of SOD: located in the cytosol, CuZnSOD (SOD1) is the predominant form and is responsible for 70%-80% of the total SOD activity in the cell (31) . In contrast, MnSOD (SOD2) resides within the mitochondrial matrix and contributes 10%-20% of overall cellular SOD activity (31) . The extracellular form (SOD3) completes the family (31) . Owing to its localization to mitochondria, SOD2 therefore provides the primary antioxidant defense against superoxide radicals produced as a by-product of the respiratory chain. Incidentally, only the SOD2 isoform has been demonstrated to be induced and regulated by ROS (32, 33) . Furthermore, although SOD2 is expressed in many regions of the brain that are affected in PD, its heterogeneous but nonubiquitous distribution suggests that not all cells are protected against the harmful effects of superoxide to the same extent (34) .
In transgenic mice, the total loss of SOD2 functionality is fatal: depending on the strain, targeted ablation of the SOD2 gene results in death either during late embryonic development or within the first 3 postnatal weeks (35) . Interestingly, mice haplodeficient for the gene are viable, fertile, and have a normal lifespan despite significantly increased DNA damage (36, 37) . These heterozygous SOD2-knockout animals exhibit reduced MnSOD activity in all tissues-typically by 50%, but this was demonstrated to be almost 80% in brain (37) (38) (39) .
In the work presented here, a well-characterized line of transgenic a-synuclein mice (overexpressing mutant A30P human a-synuclein under the control of a neuronal promoter) was bred to be haplodeficient for SOD2 in order to increase their intrinsic state of oxidative stress. An exacerbation of asynuclein aggregation was observed in these animals when compared with littermate controls wild type for SOD2.
MATERIALS AND METHODS

Animals
All animal experiments were conducted in an AAALAC-accredited facility (Association for Assessment and Accreditation of Laboratory Animal Care International) in accordance with the EU Directive 2010/63/EU for animal experiments. Authorization was granted by the Animal Care Commission of the government of Baden Württemberg, Germany (Regierungspr€ asidium Tübingen). Mice were given food and water ad libitum, while room temperature and humidity were maintained at 22 C 6 2 C and 55% 6 10%, respectively.
Transgenic heSOD2-ho[A30P]h-aSyn mice were produced by crossing B6.129S7-Sod2 tm1Leb /J mice (purchased from The Jackson Laboratory [40] ) with homozygous (Thy-1)-h[A30P]-a-synuclein mice (kindly donated by Dr. Philipp Kahle [41] 
Brain Bank
Transgenic mouse brains were removed and cut in half along the longitudinal cerebral fissure. The left half was fixed for 3 days in 10% formalin and then mounted in paraffin; the right half was split into forebrain and hindbrain sections, before being snap-frozen in liquid nitrogen and stored at À150 C until needed for protein fractionation.
PK-PET Blot
The PK-PET blot analysis was essentially performed as described by Neumann et al (41) . Briefly, sagittal sections of paraffin-embedded brain tissue were cut to a thickness of 5 mm and captured onto PVDF membrane with a pore size of 0.2 mm (Serva Electrophoresis GmbH, Heidelberg, Germany). The sections were deparaffinized and rehydrated in a series of xylol (100%), ethanol (100%, 95%, and 70%), and 1Â TBS, with 2 5-minute washes at each stage. The sections were then digested in 10 mg/mL proteinase K for 15 hours at 55 C in PK digest buffer (10 mM Tris-HCl pH 7.8, 100 mM NaCl, 0.1% Brij). Subsequent steps were carried out on a rocker. Membranes were washed in TBST, before endogenous peroxidase activity was blocked with 3% H 2 O 2 . Epitope retrieval was assisted with 15 minutes of pre-treatment in 4 M guanidinium thiocyanate, before the PK-PET blots were blocked in I-Block (Applied Biosciences, Foster City, CA) for 1 hour at room temperature. Membranes were then treated overnight at 4 C with clone 42 mouse anti-a-synuclein primary antibody (BD #610787, diluted 1: 1000), before being incubated with goat anti-mouse biotinylated secondary antibody (Vector, diluted 1: 500) for 1 hour at room temperature. A Vector VIP peroxidase substrate kit (Vector Laboratories, Burlingame, CA) was used according to the manufacturer's instructions to stain asynuclein chromogenically. Images of dried membranes were made at approximately 20-fold magnification, before Scale solution (4 M urea, 10% [w/v] glycerol, 0.1% [w/v] Triton X-100 [42] ) was used to make the membranes translucent for imaging at 200-fold magnification. The resolution at higher magnifications was found to be better if looking at reflected light in the fluorescent DAPI channel. Using this technique, it was possible to make sharper images of aggregates at 200-fold magnification, thus revealing smaller constructs that would have previously gone undetected.
Immunohistochemistry
Sagittal sections of paraffin-embedded brain tissue were cut to a thickness of 10 mm and captured onto glass slides. The tissue sections were then deparaffinized in a series of xylol and alcohol. In order to assist epitope retrieval, the sections were incubated in 10 mg/mL proteinase K for 20 minutes at 37 C, before being pre-treated for 20 minutes in 10 mM citrate buffer pH 6 at 95 C. The EP1536Y rabbit anti-a-synuclein pS129 primary antibody (Epitomics, diluted 1: 1000) was used to detect a-synuclein phosphorylated at serine 129, while an ALEXA Fluor 594 anti-rabbit secondary antibody (1 mg/ mL) was used to produce the fluorescent stain.
Protein Fractionation
Protein fractionation was performed in a similar way to that described by Tofaris et al (43) . See Supplementary Methods for more details.
Data Analysis
Statistical analyses were performed in SAS version 9.4 for Windows (SAS Institute, Inc., Cary, NC). PK-PET blot scores were analyzed using the F-test based on a generalized linear model with multinomial distribution and factors for treatment and assessor. The model considered the variability between each assessor's scores and calculated whether this influenced the result (see Supplementary Methods for details on SI Statistics). A Wilcoxon rank-sum test was applied to the densitometry analysis. Significance was deemed to be indicated by a p value 0.05. [41] and B6.129S7-Sod2 tm1Leb /J [40] -were used to generate large cohorts of mice overexpressing mutant human a-synuclein, carrying either wild type (wtSOD2-ho[A30P]h-aSyn, 27 mice) or reduced SOD2 (heSOD2-ho[A30P]h-aSyn, 72 mice) activity. The animals were routinely monitored for general well-being up to an age of 16 months, when they were killed for pathological analysis. Although in our hands the majority of these transgenic mice do not develop an overt phenotype characterized by motor deficits before reaching an age >18 months (data not shown), animals were closely observed for premature disease progression by pre-defined endpoints (rapid weight loss >20% and/or severely impaired righting reflex), triggering earlier death if mandated. In total, 2 wild-type SOD2 mice and 15 mice haplodeficient for SOD2 exhibited a positive gait phenotype; of which, 1 wild-type SOD2 mouse and 8 mice haplodeficient for SOD2 were killed early because they developed a severe phenotype (for the age of each mouse at death, refer to Supplementary Data Table S1 ).
RESULTS
Two transgenic strains-(Thy-1)-h[A30P]-a-synuclein
PK-PET Blot Analysis of a-Synuclein Aggregation
The PK-PET blot was first introduced for the analysis of a-synuclein aggregates in tissue slices by Neumann et al (41) . It has since been used extensively for the characterization of the build-up of pathologic lesions in models of a-synucleinopathy. In the work presented here, the severity of a-synuclein aggregation was assessed using a subjective 0-4 scoring system developed to grade the intensity of the PK-PET blots (Fig. 1) . A higher score indicates a more severe deposition of insoluble a-synuclein aggregates. Analysis was performed by 3 independent observers blinded to the underlying genotype of the analyzed samples (potential assessor effect was not significant: p > 0.05). Representative examples from mice with different PK-PET blot scores are presented in Figure 2 . The scoring of the PK-PET blots is summarized in Table 1 . At the time of death, significantly more mice from the cohort haplodeficient for SOD2 had reached an advanced stage of disease compared with the mice wild type for SOD2, as indicated by a greater proportion of mice with a higher median PK-PET blot score (p < 0.01). This could indicate an accelerated deposition of insoluble a-synuclein aggregates in animals with compromised detoxification of superoxide radicals owing to reduced SOD2 expression, or an earlier onset of the aggregation.
a-Synuclein pSer129 Analysis
The majority of a-synuclein in Lewy bodies (spherical somatodendritic inclusions of fibrillar a-synuclein) and Lewy neurites (filamentous axonal aggregates of a-synuclein) isolated from postmortem brains of PD patients are phosphorylated at serine 129 (44) . This is also true for a-synuclein aggregates in transgenic models of PD, making phosphorylated a-synuclein an attractive and widely used marker for histopathological analysis. Unfortunately, the peripheral position of serine 129 within the a-synuclein sequence, and thus the epitope for any antibody against phosphorylation at this location, is not compatible with a method involving a proteinase K digest, which quantitatively removes the flexible C-terminal tail of monomeric or aggregated fibrillar a-synuclein. In contrast, the BD antibody used in the PK-PET blot and Western blot analyses here binds to a more central epitope not affected by limited proteolysis of fibrillar a-synuclein. To support the PK-PET blot data, sagittal sections of paraffin-embedded brain tissue from heSOD2-ho[A30P]h-aSyn and wtSOD2-ho[A30P]h-aSyn mice were stained with the EP1536Y antibody against a-synuclein phosphorylated at the serine 129 position, omitting a proteolytic digest.
A strong stain of aggregated a-synuclein in situ was achieved with this antibody (Fig. 3) . A wide range of disease severity was observed across the different mice, and in more severely affected animals the tissue was rife with lengthy fibrillar aggregates superficially resembling Lewy neurites. Furthermore, the degree of a-synuclein aggregation exhibited in the immunohistochemical analyses correlated well with the PK-PET blot scores already assigned to each mouse (Supplementary Data Table S1 ).
Western Blot Analysis of a-Synuclein in the Insoluble Fraction of Transgenic Brain
In order to extend the analysis toward a semiquantitative method based on measuring the accumulation of aggregated fibrillar a-synuclein inclusions, protein fractionation was performed on the remaining sagittal half of the brain from the 16-month-old heSOD2-ho[A30P]h-aSyn and wtSOD2-ho[A30P]h-aSyn mice. The purpose of this was to isolate the insoluble species of a-synuclein sequestered into aggregates in pathologic mutant brain, thereby addressing the inherent spatial heterogeneity of the a-synuclein animal model, which is discernible in the PK-PET blots. Transgenic brain homogenates were partitioned into 3 fractions containing soluble a-synuclein, SDS-soluble a-synuclein, and insoluble a-synuclein, respectively. Animals displaying motor deficits resulting from a massive deposition of aggregated, fibrillar a-synuclein present with particular Cand N-terminally truncated a-synuclein species, as described previously by others including Neumann et al (41, (45) (46) (47) . For the purpose of this study, only the insoluble fraction was analyzed for each mouse. The intensity of the band at the position of monomeric a-synuclein (corresponding to a molecular weight of $14 kDa) did not correlate with the degree of a-synuclein aggregation. However, large variations in the amount of at least 4 different truncated species of a-synuclein were observed between samples (Fig. 4) . In addition, bands of a higher molecular weight than the a-synuclein monomer also varied between samples. A higher amount of truncated a-synuclein in the insoluble fraction correlated with a higher score in the PK-PET blot (raw data are summarized in Supplementary Data Table S1 ).
In order to gauge the load of pathologic synuclein species in each mouse, the intensity of the insoluble-fractionspecific bands with apparent molecular weights below 12.5 kDa was measured by densitometry. The results of the densitometry analysis for each cohort were then analyzed by Wilcoxon rank-sum test (Table 2; refer to Supplementary  Data Table S1 for the measured intensity of each mouse). The intensity of the bands observed in the mice haplodeficient for SOD2 was significantly greater than that measured in the cohort wild type for SOD2 (p < 0.05). This indicates a greater build-up of insoluble deposits of aggregated fibrillar a-synuclein in the transgenic a-synuclein mice with decreased SOD2 activity.
For the complete read-out profile of a typical mouse from each PK-PET blot score category, including the Western blot analysis of the insoluble fraction from protein fractionation, refer to Supplementary Data Figure S4 . The presence of 2 truncated species of a-synuclein in the insoluble fraction correlated with a more advanced stage of synucleinopathy in the affected animals.
Overall, the data presented here indicate an exacerbation of a-synuclein aggregation in a genetic murine model with compromised ROS defense, resulting from a partial loss of detoxifying SOD2 activity.
DISCUSSION
Available data suggest that oxidative stress emanating from dysfunctional mitochondria could play a key role in PD pathogenesis. Indeed, oxidative damage is present in PD brain (48) (49) (50) (51) (52) (53) , whereas an apparent interaction between dysfunctional mitochondria and a-synuclein appears to exacerbate neuropathology (14) (15) (16) (17) (18) (19) (20) . Moreover, oxidative stress can induce a-synuclein aggregation in vitro (21, 22) . In this study, (Thy-1)-h[A30P]-a-synuclein mice were crossed with FIGURE 1. Scoring system for the evaluation of PK-PET blots. Five-lm-thick paraffin-embedded tissue sections were captured onto PVDF membranes and de-paraffinized, before being digested overnight in 10 lg/mL proteinase K. The BD antibody was then used to stain a-synuclein and the membranes were subsequently scored according to the severity of a-synuclein aggregation using the following criteria: (4) excessive pathologic lesions in the hindbrain and brain stem, plus prominent involvement of the cerebellum; (3) strong aggregation in the hindbrain and brain stem, with only weak staining in the cerebellum; (2) recognizable staining in the hindbrain and brainstem; (1) some grouped punctate staining, without clear identification of the involved brain area; (0) no significant staining; (C) non-digested control. As a frame of reference, each tissue section is positioned on the blot in approximately the same place as the control; for further assistance with orientation, refer to Supplementary Data Figure S3 , where each blot has been annotated with the approximate outline of the tissue section. See Figure 2 for a further 3 series of PK-PET blots including the full range of scores. CB, cerebellum; MB, midbrain; P, pons; M, medulla.
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tm1Leb /J animals to produce a novel double transgenic line that overexpressed mutant human a-synuclein while being haplodeficient for SOD2: heSOD2-ho[A30P]haSyn. By reducing the capacity of SOD2 in these mice, and thus compromising the primary antioxidant defense machinery of the mitochondria, we increased mitochondrial oxidative stress in order to investigate its long-term influence on the deposition of a-synuclein lesions in an established in vivo model. The results indicate that elevated levels of intrinsic oxidative stress could modulate a-synuclein aggregation in vivo, ultimately driving the progression of synucleinopathy. Similar findings have been reported in the context of Alzheimer FIGURE 2. Example PK-PET blot analyses of transgenic mouse brain. Five-lm-thick paraffin-embedded tissue sections were captured onto PVDF membranes and underwent PK PET blot analysis. The samples were subsequently scored using the grading system described in Figure 1 . Shown here are 3 typical representative blots for each grade. The tissue sections are positioned and orientated in approximately the same place on each blot; see Supplementary Data Figure S3 for an anatomical frame of reference. CB, cerebellum; MB, midbrain; P, pons; M, medulla. 
Analysis of a-Synuclein Aggregation
The inherent characteristics of a-synuclein lesions can be used to identify pathology in PD brain or equivalent animal models: the phosphorylation of a-synuclein at serine 129 (57) is a specific marker for its aggregation (44) , whereas the fibrillar conformation of the protein within aggregates turns it resistant to limited proteolysis (58) . Taken together with the highly insoluble nature of a-synuclein inclusions, this establishes a robust battery of 3 complementary methods that can be used to characterize the pathological profile of a-synuclein aggregation: immunohistochemical staining of pSer129, isolation of the insoluble fraction of brain homogenate, and digestion of soluble a-synuclein via PK-PET blot. Hence, these methods were used to compare the a-synuclein aggregation exhibited by the heSOD2-ho[A30P]h-aSyn line carrying compromised ROS defense with that of wtSOD2-ho[A30P]h-aSyn mice carrying full SOD2 functionality.
All mice were killed for analysis at an age of 16 months, with the exception of those mice that had to be killed early because they developed a severe positive gait phenotype based on predefined behavioral endpoints (i.e. rapid weight loss >20% and/or severely impaired righting reflex: 8 mice haplodeficient for SOD2 and 1 mouse wild type for SOD2). The earlier death of severely phenotypic animals was not considered to have affected the results, since these mice had Table S1 . He, heterozygous for SOD2 KO allele; Wt, wild type for SOD2 allele; red genotypes denote mice exhibiting a compromised righting reflex (i.e. positive disease phenotype). (41), the gait appeared much later in subsequent studies (18 months) (45, 47) . In line with the 2 later reports, the (Thy-1)-h[A30P]-a-synuclein mice bred in our facility typically developed motor dysfunction at an age >18 months with a large amount of variability (data not shown). Therefore, the age of 16 months was selected as a prephenotypic stage for a sensitive comparison of the degree of synucleinopathy exhibited by wtSOD2-ho[A30P]h-aSyn and heSOD2-ho[A30P]h-aSyn animals, allowing the detection of divergent disease progression in animals with compromised SOD2 enzymatic activity. The authors are unaware of any earlier attempts to analyze PK-PET blots quantitatively in previous studies. For the sake of the work presented here, and because a range of aggregate accumulation was expected, a blinded subjective scoring system was developed in order to evaluate the severity of synucleinopathy present in each individual animal. The validity of this scoring system was supported by the results obtained from the other 2 analyses that were performed. Indeed, a higher PK-PET blot score (denoting the presence of more proteinase-K-resistant aggregates on the blot) correlated well with stronger band intensity in the Western blot analysis of the insoluble fraction isolated from brain homogenate, and with an extensive immunohistochemical stain for pSer129.
The Western blot analysis of wtSOD2-ho[A30P]h-aSyn and heSOD2-ho[A30P]h-aSyn mice was based on the intensity of bands representing truncated species of a-synuclein. These bands were only present in the insoluble fraction of brain homogenates, and their appearance and intensity correlated with the progression of disease. Indeed, the bands were ever-present and most intense in the insoluble fractions from mice that were killed after exhibiting severe debilitation from their phenotype (Supplementary Data Table S1 ). At least 4 different species of truncated a-synuclein could be identified in some of the samples. In contrast, the bands were non-existent in the insoluble fractions from healthy mice with little to no aggregation formation.
This characteristic of the pathologic lesions exhibited by the mice presented here could be relevant to Parkinsonian pathology in humans. Indeed, the truncation of a-synuclein is a constitutive posttranslational modification that occurs in vivo and which bears relevance to PD since a-synuclein fragments are typically associated with Lewy bodies (59, 60) . The most common cleavage removes between 5 and 25 amino acids from the C-terminal end (61); the resulting fragments aggregate more readily than full-length a-synuclein in vitro, which has led some to suggest that truncation could be responsible for provoking aggregation in vivo (59, 62, 63) . In addition, the monomeric state of the protein is disrupted if the C-terminus (which is responsible for the intrinsic chaperone functionality of a-synuclein) is completely removed, also resulting in accelerated aggregation of the protein (64, 65) . The increased propensity of truncated a-synuclein to aggregate was confirmed in vivo, and this correlated with greater toxicity. Interestingly, co-expression of truncated a-synuclein with the full-length protein appeared to have a precipitating effect in dopaminergic SH-SY5Y cells and increased their vulnerability to oxidative stress (59, 66) ; this neurotoxicity was mirrored in transgenic mice co-expressing truncated a-synuclein with full-length a-synuclein, including definitive neurodegeneration in the substantia nigra (43, (67) (68) (69) .
SOD2 Deficiency Exacerbates a-Synuclein Aggregation in heSOD2-ho[A30P]h-a-Syn Mice
The results presented here demonstrate that a reduced capacity of SOD2, an essential member of the cellular antioxidant defense machinery, exacerbated the a-synuclein aggregation exhibited by transgenic mice overexpressing mutant human a-synuclein. Indeed, at 16 months of age, significantly more heSOD2-ho[A30P]h-aSyn mice had entered a later stage of a-synuclein aggregation when compared with wtSOD2-ho[A30P]h-aSyn animals, as shown by higher PK-PET blot scores (Table 1 ) and a greater amount of truncated a-synuclein detected in the Western blot analysis of the insoluble fraction of brain homogenates (Table 2 ). This is an indication that a perturbation of the scavenging of free radicals can exacerbate a-synuclein aggregation in vivo. The work presented here supports studies in which oxidative stressors were shown to induce a-synuclein aggregation in vivo (19, 20) , and substantiates the evidence for an interaction between oxidative stress and a-synuclein-exacerbating disease (15) (16) (17) (18) . Furthermore, since SOD2 deficiency accelerated disease progression in mouse models of AD (54, 55, 70) and ALS (56) , this implies a more general role for oxidative stress in the modulation of pathologic states in neurodegenerative diseases.
Nevertheless, exactly how increased oxidative stress provokes the aggregation of a-synuclein remains a matter for speculation. Apart from a potential role in directly driving accelerated aggregation of the protein (21, 71) , aging and increased levels of oxidative stress could overload the proteostasis network, especially within the long-lived cells of the central nervous system (reviewed in Korovila et al [72] and Yerbury et al [73] ). Recent work on the prion-like spreading of a-synuclein (pioneered by the Lee lab [74] and independently confirmed by several other labs [75] [76] [77] ) suggests that fibrillar a-synuclein released from dying or compromised neurons is taken up via endocytosis into healthy neighboring cells (78) . While most of the aggregates that are taken up would then be degraded in the lysosome (79, 80) , it could be envisioned that a disturbed cellular homeostasis resulting from elevated oxidative stress would compromise the cellular capacity to cope with this aggregate load. The likelihood of endosomal/ lysosomal escape by aggregated a-synuclein would therefore be increased, allowing the seeding of new intracellular aggregates in the healthy neuron. The potential impact of compromising the cell's ability to catabolize aggregated asynuclein was recently demonstrated with pharmacological interventions perturbing lysosomal functions (81, 82) , increasing the rate of inclusion formation in cellular models of PD.
optimal for research. The observed large variability regarding the age at onset of symptoms dictates a long-term follow-up for the characterization of a-synuclein aggregation; however, once the motor phenotype appears, the progression to spastic paralysis and death requires only a few weeks (41) . Since the length of survival and the severity of oxidative stress observed in SOD2 knockout mice are considerably affected by genetic background (35) , implementation of an a-synuclein-dependent disease model with faster onset of pathological changes (83) could be envisioned. In a similar vein, it would be interesting to transfer the focus of pathology to a more PD-relevant area of the brain by reducing SOD2 in a different line of transgenic a-synuclein mice. Indeed, expression of truncated a-synuclein under the control of the TH promoter provokes aggregate formation in the substantia nigra (43) . The fact that these neurons are dopaminergic could also have an effect on the course of disease as dopamine can be oxidized easily, thus adding a source of oxidative stress potentially relevant to PD. This could represent a major contributing factor to the specific vulnerability of dopaminergic neurons to neurodegeneration. By extension, one could implement the well-characterized 6-OHDA model of PD employing dopamine-related oxidative stress.
In a more recent model of synucleinopathy, injection of fibrillar a-synuclein either to the brain (74, 84) or to the hind limb (85) of transgenic mice was able to induce widespread asynuclein aggregation in the central nervous system that was accompanied by debilitating motor impairment. It would be interesting to see if SOD2 deficiency could exacerbate this process in these animals.
Conclusion
Here, a novel double transgenic line was developed with overexpressed A30P mutant human a-synuclein and haplodeficient SOD2, an essential mitochondrial antioxidant enzyme. When compared with littermates expressing mutant human asynuclein with complete SOD2 functionality, these transgenic mice exhibited an exacerbation of a-synuclein aggregation characteristic of PD. The results indicate that a compromise in the capacity to scavenge free radicals can drive a-synuclein aggregation, and thus elevated levels of oxidative stress could modulate the progression of PD. This supports a potential therapeutic role for antioxidant therapy in PD, as has been proposed for AD (86, 87) . Indeed, the maintenance of uninhibited activity of the mitochondrial antioxidant defense machinery could prevent the early onset of disease symptoms, whereas augmenting this system might slow or even stop disease progression in PD.
